Thus, incretin hormones have proven to be useful parent compounds for therapeutic peptides, and the expectations regarding their use for the treatment of diabetes, obesity and associated cardiorenal complications are high. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.